Industry Payments During the COVID-19 Pandemic to Cardiologists in the United States

In the US, research has established that a funding relationship exists between pharmaceutical industries and physicians, particularly cardiologists. This study aimed to fill a research gap via an in-depth data analysis of the impact that the coronavirus 2019 restrictions had on this dynamic. The pay...

Descripción completa

Detalles Bibliográficos
Autores principales: Murayama, Anju, Kamamoto, Sae, Shigeta, Haruki, Ozaki, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Emerging Evidence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812463/
https://www.ncbi.nlm.nih.gov/pubmed/36624880
http://dx.doi.org/10.1016/j.cjco.2023.01.001
Descripción
Sumario:In the US, research has established that a funding relationship exists between pharmaceutical industries and physicians, particularly cardiologists. This study aimed to fill a research gap via an in-depth data analysis of the impact that the coronavirus 2019 restrictions had on this dynamic. The payments per cardiologist declined by 55.7% (95% confidence interval: 52.0%‒-59.0%, P < 0.001) in monetary amounts, and by 66.6% (95% confidence interval: 66.1%-67.1%, P < 0.001) in the number of payments right after the COVID-19 pandemic onset, respectively. Cardiologists must consider the ethical implications of the potential for their clinical practice to be influenced by industry payments.

Ejemplares similares